Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study by Ruopeng Su, Zeyu Chen, Daoping Hong, Shuai Jiang, Yichu Yuan, Xingyun Cai, Hailong Hu, Changde Fu, Zhiyang Huang, Zhenyu Wang, Bing Zheng, Jian Huang, Zaoyu Wang, Yige Bao, Ming Cai, Jianming Guo, Minfeng Chen, Qiang Wei, Jiwei Huang, Wei Xue

Subjects: Get full text

Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis by Huitao Wang, Jianhe Liu, Kewei Fang, Changxing Ke, Yongming Jiang, Guang Wang, Tongxin Yang, Tao Chen, Xin Shi

Subjects: Get full text

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemc... by Jiwei Huang, Ruopeng Su, Zeyu Chen, Shuai Jiang, Minfeng Chen, Yichu Yuan, Hailong Hu, Changde Fu, Zhiyang Huang, Zhenyu Wang, Bing Zheng, Chancan Li, Zaoyu Wang, Yige Bao, Ming Cai, Jianming Guo, Qiang Wei, Wei Xue

Subjects: Get full text

Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand? by Mohammad Jad Moussa, Matthew T. Campbell, Omar Alhalabi

Subjects: Get full text